Literature DB >> 9145595

Resistance of Vibrio cholerae 01 to nalidixic acid.

M V Jesudason1, R Saaya.   

Abstract

Until 1987 all isolates of V. cholerae 01 at a tertiary care hospital in south India were susceptible to drugs commonly used to treat gastroenteritis including cholera. Since July 1987 strains resistant to co-trimoxazole have been encountered and since October 1995 strains resistant to nalidixic acid are being isolated. In this study the latter strains were examined by determining minimum inhibitory concentration levels of nalidixic acid as well as norfloxacin, the fluoroquinolone extensively used to treat diarrhoea. No cross resistance to norfloxacin was found in any of the nalidixic acid resistant V. cholerae 01 strains.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9145595

Source DB:  PubMed          Journal:  Indian J Med Res        ISSN: 0971-5916            Impact factor:   2.375


  4 in total

Review 1.  Epidemiology, genetics, and ecology of toxigenic Vibrio cholerae.

Authors:  S M Faruque; M J Albert; J J Mekalanos
Journal:  Microbiol Mol Biol Rev       Date:  1998-12       Impact factor: 11.056

2.  Increasing antimicrobial resistance of Vibrio cholerae OI biotype E1 tor strains isolated in a tertiary-care centre in India.

Authors:  Jharna Mandal; K P Dinoop; Subhash Chandra Parija
Journal:  J Health Popul Nutr       Date:  2012-03       Impact factor: 2.000

3.  Efficacy of Ciprofloxacin for Treatment of Cholera Associated with Diminished Susceptibility to Ciprofloxacin to Vibrio cholerae O1.

Authors:  Wasif Ali Khan; Debasish Saha; Sabeena Ahmed; Mohammed Abdus Salam; Michael Louis Bennish
Journal:  PLoS One       Date:  2015-08-13       Impact factor: 3.240

Review 4.  Changing facades of Vibrio cholerae: An enigma in the epidemiology of cholera.

Authors:  N Lekshmi; Iype Joseph; T Ramamurthy; Sabu Thomas
Journal:  Indian J Med Res       Date:  2018-02       Impact factor: 2.375

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.